Ranganath and colleagues also tracked changes in RA medications as a surrogate for disease activity
(Reference Gayatri, Kumar and Kumar28) , participants were not randomly assigned to the intervention and control groups, and seven studies described an allocation concealment method (Reference Hassan, Alalfy and Hassan18,Reference Badawy, El Nashar and El Totongy20Reference Hashim, Anwar and El-Fatah22,Reference Elgindy, El-Huseiny and Mostafa23,Reference Ghomian, Khadem and Moeindarbari5,Reference Maged, Elsawah and Abdelhafez8)
The company received a $150,000 fine for, among other things, making claims about GLP-1 effectiveness without proper evidence, and manipulating consumer reviews
I live in Saskatoon, Saskatchewan and I turned 46 this past spring
One of the promising therapies we offer is semaglutide, a GLP-1 receptor agonist that has gained recognition for its remarkable efficacy in aiding weight loss